Entrada Therapeutics, Inc. (TRDA)
| Market Cap | 239.98M -18.3% |
| Revenue (ttm) | 5.74M -96.7% |
| Net Income | -166.12M |
| EPS | -4.00 |
| Shares Out | 36.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,031 |
| Open | 6.58 |
| Previous Close | 6.31 |
| Day's Range | 6.58 - 6.73 |
| 52-Week Range | 4.93 - 16.45 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 19.50 (+192.79%) |
| Earnings Date | May 7, 2026 |
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was f... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price target is $19.5, which is an increase of 192.79% from the latest price.
News
Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted a novel EEV platform enabling efficient drug delivery and a DMD program showing strong safety and early functional benefit signals. Ongoing trials are escalating doses to optimize efficacy, with multiple data readouts and new ophthalmology candidates expected in 2024–2025.
Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Entrada Therapeutics, Inc. (NASDAQ: TRDA). The investigation focuses on Ent...
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics NASDAQ: TRDA said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory...
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a Buy rating on the shares. The Phase 1/2 study Cohort 1 results…
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying the ELEVATE-44-201 initial cohort data “underwhelm.” The functional ...
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study. ELEVATE-44-201...
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
Reports Q1 revenue $875,000, consensus $2.92M. “With the recently announced positive data from Cohort 1 of our ELEVATE-44-201 clinical study, this year has already delivered a significant clinical inf...
Entrada Therapeutics Transcript: Study result
Cohort 1 of the ELEVATE-44-201 study showed ENTR-601-44 was safe and led to significant functional improvement in DMD patients, despite lower than expected dystrophin levels. Higher doses in upcoming cohorts are expected to further increase dystrophin and functional benefit.
Entrada Therapeutics Press release: Study result
Entrada Therapeutics issued a press release on May 7, 2026, disclosing material business information to investors.
Entrada Therapeutics Slides: Study result
Entrada Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Entrada Therapeutics Reports First Quarter 2026 Financial Results
500 - Internal server error. Server Error 500 - Internal server error.
Entrada's Duchenne drug shown to improve muscle function in early trial
Entrada Therapeutics said on Thursday its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease, in an early-to-mid sta...
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all...
Entrada Therapeutics Quarterly report: Q1 2026
Entrada Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Entrada Therapeutics Earnings release: Q1 2026
Entrada Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
Entrada Therapeutics Proxy statement: Proxy filing
Entrada Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Entrada Therapeutics Proxy statement: Proxy filing
Entrada Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Entrada Therapeutics Proxy statement: Proxy filing
Entrada Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
Oppenheimer raised the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $21 and keeps an Outperform rating on the shares. The firm hosted management for an investor call…
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Entrada is developing a cyclic cell-penetrating peptide platform aimed at overcoming key drug delivery ch...
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating.
Entrada Therapeutics management to meet with Oppenheimer
Meeting to be held on April 2 hosted by Oppenheimer.
Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Multiple clinical readouts are expected in 2026 for DMD and DM1, with a focus on best-in-class dystrophin production and a robust cash runway into Q3 2027. Expansion into ocular diseases and a strong Vertex partnership support pipeline growth and regulatory progress.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired ...